ZSAN Zosano Pharma Corp

Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update

Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update

FREMONT, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, November 14, 2019 at 4:30 p.m. ET to discuss results for the third quarter of 2019 and provide an operational update. The Company will announce its financial results for this period in a press release to be issued prior to the call.

To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at . Alternatively, you may access the live conference call by dialing (844) 379-5311 (U.S.) or (209) 905-5963 (international). The conference ID number is 5284737.

A replay will be available on the company's website approximately three hours after the call and available through December 14, 2019.

About Zosano Pharma

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on developing products where rapid administration of molecules with demonstrated safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s Adhesive Dermally-Applied Microarray (ADAM) technology consists of titanium micro-projections coated with drug that is designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is QtryptaTM (M207), which is an investigational, proprietary formulation of zolmitriptan delivered via ADAM technology, currently in development for the acute treatment of migraine. In February 2017, the company announced positive and statistically significant results from the ZOTRIP pivotal study, and in February 2019, the company announced the completion of the final milestone in its long-term safety study. The company is preparing to submit a New Drug Application to the Food and Drug Administration for Qtrypta (M207). Learn more at .

Zosano Contact:

Greg Kitchener

Chief Financial Officer

510-745-1200

PR Contact:

Sylvia Wheeler (or Alexandra Santos)

/

EN
07/11/2019

Underlying

ZSANZosano Pharma Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zosano Pharma Corp

 PRESS RELEASE
Free
ZSAN Zosano Pharma C...

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11 FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a “debtor-in-poss...

June 2, 2022 1 EN
 PRESS RELEASE
Free
ZSAN Zosano Pharma C...

Zosano Pharma Reports First Quarter 2022 Financial Results

Zosano Pharma Reports First Quarter 2022 Financial Results FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared wit...

May 13, 2022 1 EN
 PRESS RELEASE
Free
ZSAN Zosano Pharma C...

Zosano Pharma Provides Corporate Update

Zosano Pharma Provides Corporate Update FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its M207 New Drug Application. However, in order to preserve its capital and cash resources, Zosano has suspended its M207 program. Additionally, the company’s remaining feasibility study with a pharmaceutical partner is expected to conclude this quarter. Zos...

April 29, 2022 1 EN
 PRESS RELEASE
Free
ZSAN Zosano Pharma C...

Zosano Pharma Announces Reverse Stock Split Effective Today

Zosano Pharma Announces Reverse Stock Split Effective Today ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022 FREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock. The reverse stock split will become effective today, April 11, 2022. The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on April 12, 202...

April 11, 2022 1 EN
 PRESS RELEASE
Free
ZSAN Zosano Pharma C...

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Re...

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. “We are in discussions with the FDA to determine if there is a viable option to pursue approval of M207 using the currently available clinical data. In addition, we are actively evaluating financial and strategic alternatives in collaboration with external advi...

March 17, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch